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PREFACE
“We have the self-awareness to be honest with ourselves to say, “we have been part of the
problem, and we have to be part of the solution”
~Jonathan Brown, CEO, Indian Stream Health Center
Regarding opioid prescribing and efforts to combat the opioid epidemic
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ABSTRACT
The concurrent use of opioids and benzodiazepines (BZDs poses a formidable challenge for
clinicians who manage chronic pain. While the escalating use of opioid analgesics for the
treatment of chronic pain and the concomitant rise in opioid-related abuse and misuse are
widely recognized trends, the contribution of combination use of BZDs, alcohol, and/or other
sedative agents to opioid-related morbidity and mortality is underappreciated, even when
these agents are used appropriately. Patients with chronic pain who use opioid analgesics
along with BZDs have a defined increase in rates of adverse events, overdose, and death,
warranting close monitoring. To improve patient outcomes, ongoing screening for aberrant
behavior, monitoring of treatment compliance, documenting medical necessity, and e
adjusting treatment in response to clinical changes are essential. National and state
guidelines recommend that patients on chronic opioid therapy (COT) should periodically
undergo urine drug testing and a review of prescription drug monitoring program to confirm
adherence to the treatment plan. These guidelines also recommend reviewing the
prevalence and pharmacologic consequences of BZDs among patients on COT. This DNP
Project evaluated the effectiveness of the implementation of a quarterly triad tool (QTT),
which included (a) current urine drug testing and (b) prescription drug monitoring, with (c)
the addition of medication reconciliation for concomitant BZD use (CBU) on mitigation of
adverse event risks in patients treated for chronic pain in a pain clinic in central Indiana. One
of six providers did not adopt the practice change; but 151 of 154 patients were screened
using the QTT, and 24 (15.89%) had CBU detected. Documentation of risk education
increased from 25% pre-intervention to 100% post-intervention (X2(1) = 10.59, p = .001).
Follow-up plan documentation also increased to a statistically significant level: 5% preintervention to 75% post-intervention (X2(1) = 8.24, p = .004).
Keywords: quarterly triad tool, opioids, benzodiazepines, chronic pain
viii
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CHAPTER 1
INTRODUCTION
Background
Chronic pain continues to be a multidimensional problem for people in the United States
of America. The experience of pain has been recognized as a national public health problem
with profound physical, emotional and societal costs (U.S. Department of Health and Human
Services [USDHHS], 2018). Today, chronic pain affects an estimated 50 million U.S. adults and
as many as 19.6 million of those adults experience high-impact chronic pain that interferes with
daily life of work activities (USDHHS, 2018). Primary care providers, as well as pain
management specialists, often rely on opioids to control chronic pain. However, the use of these
potent medications must be balanced against their risk for harmful adverse effects, which range
from constipation to respiratory arrest. In particular, the prevalence of psychological
dependence on opioids has increased at an unprecedented rate in many regions throughout the
United States (USDHHS, 2018). This chapter will provide a summary of the background and
significance of the recent “opioid epidemic” and describe the purpose of this project in the
context of chronic pain management.
Statement of the Problem
In the US, the increased use of prescription opioids and the resulting potential for
addiction and overdose impose substantial public health burden of morbidity, mortality and
economic costs (Sun et al., 2017). From 1999-2014, more than 165,000 persons died from
overdose related to opioid pain medication in the United states (Centers for Disease Control and
Prevention [CDC], 2016). According to Sun et al. (2017), approximately 30% of fatal “opioid”
overdoses also involve benzodiazepines, which are often used concurrently with opioids, raising
the possibility that some of the increase in opioid related deaths could be caused by concurrent
benzodiazepine/opioid use over time.
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Data from the Literature Supporting Need for the Project
In addition to the overuse and abuse of opioids, the use of non-opioid substances (e.g.,
benzodiazepines) to manage the psychological effects of chronic pain adds an additional layer
of complexity to the opioid epidemic. Benzodiazepines have been commonly used to treat
anxiety and insomnia in patients with chronic pain. However, combined benzodiazepine and
opioid use is increasingly implicated in emergency department visits and drug overdoses (Park
et al., 2016). Moreover, use of benzodiazepines without a prescription has been associated with
increased risk for the development of opioid use disorder (Park et al., 2016). This is mainly due
to the enhanced pain relief, increased sense of euphoria, and availability of these substances in
the primary care setting and through non-prescribed means. Sun et al. (2017) found that 9% of
opioid users also used a benzodiazepine in 2001, increasing to 17% in 2013 (80% relative
increase).
According to Park et al. (2016), substance use disorder treatment admissions reporting
both benzodiazepine and opioid analgesic use increased 570% between 2000 and 2010,
whereas admissions that involved neither of these drugs decreased by 9.6%. These admissions
increase healthcare costs, which result in devastation of households, governments, and the
private sector. Prospective gains of mitigating combine benzodiazepine-opioid-related
admissions include healthcare costs savings and lower spending on other cascade expenses
(e.g., law enforcement). This can result in overall economic returns to households, the private
sector and the government, allowing allocation of funds to other initiatives (e.g., public school
systems).
In summary, chronic pain and opioid use disorder, particularly when combined with the
use of benzodiazepines, are two conditions that have potentially devastating consequences for
patients, their families, their communities, and the healthcare system. As evidence suggests,
the apparent need for an evidence-based approach in identifying and mitigating this risk for
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opioid use disorder, while effectively managing chronic pain, is crucial. Pain management
providers who routinely care for patients on COT should engage in a routine assessment and
evaluation of risk factors which could consequently result in an overall reduction of deaths
affiliated with prescription opioids.
Strategies to prevent opioid-related deaths include (a) routinely evaluating for risk factors
of opioid overdose or addiction, (b) checking prescription drug monitoring programs (PDMP) for
concurrent use of opioids and other controlled substances, and (c) conducting urine drug screen
(UDS) to confirm compliance with treatment plans (CDC, 2016). However, these efforts have
been largely unsuccessful due to limited access to pain management experts, inconsistent use
of opioid surveillance programs, and variable social support for responsible opioid use.
Leichtling et al. (2016) stated that in most states, PDMPS are not yet accessed by prescribers
routinely and consistently; to address this gap, many states have mandated the use of PDMP,
though conditions under which use is required vary greatly.
Prescription drug monitoring programs (PDMPs) are a key element in the identification
of concurrent prescriptions of controlled substances. Guidelines from the American Pain Society
recommend individual risk gradation with patients receiving long-term opioids to determine
frequency of monitoring, with a variety of tools (e.g., monitoring stable patients at least every
three to six months). The CDC guidelines for opioid prescribing in patients in COT recommend
PDMP review ranging from each time of prescribing to every 3 months. A qualitative study by
Leichtling et al. (2016) revealed that PDMP use varied from consistent monitoring on a
scheduled basis to checking the PDMP only on suspicion of misuse, with inconsistent use
reported particularly among short time prescribers and with existing patients of long-term
prescribers. This evidence supports the need for utilization of a standardized approach to using
PDMP with the hypothesized primary goal of promoting compliance and a secondary goal of risk
identification and mitigation with regards to concomitant benzodiazepine-opioid use (CBU).
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Data from the Clinical Agency Supporting Need for the Project
The clinical setting for this project was an outpatient pain management center in Central
Indiana. Providers at this facility included three pain management physicians, two physician
assistants (PAs), and one adult geriatric primary care nurse practitioner (AGPCNP). Although
provider patient loads vary by the type of visit; new patient visit or monthly return, on average
about 20 to 25 patients on long-term opioids are seen for their quarterly visit (third month visit).
A comprehensive approach to pain management including non-pharmacological interventions,
physical therapy, and analgesics (opioid and non-opioid) was utilized as the standard of
practice. However, there was no standardized system for monitoring patients on COT for
features of opioid use disorder and concurrent benzodiazepine use. Providers at this site
typically used either a random urine drug screen (UDS) or PDMP, which screened for the
quantity of opioids that had been prescribed and distributed to the patient over a period of time.
Informal patterns of assessing CBU likely linked to a review of medication reconciliation at each
clinic visit and a random UDS were apparent in the preliminary data. Yet, consistency was not
shown in the evaluation of CBU at each visit. This project was necessary at this facility given
that several patients currently receiving chronic opioid therapy (COT) were also taking
benzodiazepines. As a facility, there was a drive to promote safe opioid prescribing with
adherence to the recommended CDC guidelines. As a part of this initiative, the leadership had
incorporated a psychologist to address cognitive behavioral treatment (CBT) options that would
eliminate the need for benzodiazepine use and allow for the lowest dose of opioid use for
chronic pain management. Park et al. (2016) found that approximately 40% of patients who are
prescribed an opioid are also prescribed a benzodiazepine. This same pattern of CBU had been
noted at the facility, prompting administrative staff to push providers to evaluate for CBU and to
utilize evidence-based practice (EBP) options to eliminate CBU. In an attempt to improve patient
safety by decreasing concurrent opioid and benzodiazepine use, a discussion with the clinic
administrator revealed that this project was imperative.
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Purpose of the Evidence-Based Practice Project
Compelling Clinical Question
The compelling clinical query that this project addresses was as follows: What evidencebased strategies are effective in increasing healthcare providers’ use of PDMPs, UDSs, and
CBU monitoring among patients on COT? A literature search and appraisal allowed for an
evidence-based approach to the creation and utility of a tool that was utilized in the clinic by
providers during their routine quarterly visits during the time of project implementation.
PICOT Question
The PICOT question for this evidence-based practice project was as follows Among pain
management providers (P), does the use of a standardized quarterly triad tool (QTT) consisting
of PDMP, UDS, and medication reconciliation for CBU (I), compared to the current practice of
PDMP or UDS only (C), increase the monitoring of CBU and providers initiation of a
benzodiazepine specific follow up plan (O) over a 90-day period (T)?
Significance of the EBP Project
The 2016 CDC guideline for prescribing opioids for chronic pain includes a
recommendation for the routine evaluation of risk factors for opioid-related harms and ways to
mitigate patient risk (CDC, 2016).The guidelines also recommend reviewing of PDMP data,
using urine drug testing, and avoidance of co-prescribing benzodiazepines whenever possible.
The intervention within this EBP project was intended to promote the assessment of CBU by
providers, with the goal of promoting provider adherence to the use of the tool and ultimately
reducing opioid and benzodiazepine co-prescribing among patients on long-term opioid therapy.
The intervention was also intended to trigger follow up planning of affected patients by
providers.
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CHAPTER 2
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE
Theoretical Framework
With the consideration of the necessity for a systematic approach to aid in the success
of the project, the DNP student facilitator elected to incorporate John Kotter’s model of change
as the theoretical framework to guide practice change. The following narrative provides an
overview of Kotter’s model and details its application to this EBP project.
Overview of Theoretical Framework
Based on information gathered during interviews from more than 100 organizations in
the process of large-scale change, John Kotter, in his work with Dan Cohen, proposed that the
key to organizational change was founded in helping people to feel differently (i.e., appealing to
their emotions) (Melynk & Fineout-Overholt, 2015). Kotter asserted that individuals change their
behavior less when they are given the facts or analyses that change their thinking than when
individuals are shown truths that influence their feelings. (Melynk & Fineout-Overholt, 2015).
This model was determined to be ideal for the implementation of this project due to its clarity of
purpose and the assertion of the seeing, feeling and changing pattern necessary for successful
behavioral change. It is outlined in eight steps which include; (a) creating a sense of urgency for
the project, (b) building a guiding coalition, (c) forming a strategic vision and initiatives, (d)
enlisting a voluntary army and buy in, (e) empowering others to action and removing all barriers
of behavioral change, (f) generating short-term wins, (g) sustaining acceleration, and (h)
nourishing the new culture to allow for change transmission, where the new change becomes
the norm (Kotter International, Inc., n.d.)
Application of Theoretical Framework to EBP Project
The first step of the Kotter’s model of change is the creation of a sense of urgency. In
this step, the DNP student facilitator helps others to see the need for change through a bold,

CONCURRENT BENZODIAZEPINE-OPIOID SCREENING

7

aspirational opportunity statement that communicates the importance of acting immediately
(Kotter International, Inc., n.d.). Melnyk and Fineout-Overholt (2015) stated that the creation of a
sense of urgency is especially important when individuals in an organization have been in a rut
or a period of complacency for some time. A sense of urgency was established after the DNP
student discussed national necessity data as indicated in Chapter 1 of this DNP Project Report,
which included increased risk for overdose, death, and hospital admission, as well as healthcare
cost. Internal data of patients from the clinic who were impacted was also shared.
A preliminary review conducted in September 2018 revealed that approximately 30% of
patients who were on COT were also taking benzodiazepines. Although there was an effort by
the prescribing providers to limit concurrent opioid-benzodiazepine use (CBU), there also was
considerable variation in the processes of identifying CBU, as well as the timing of screening
and designated intervention across the span of providers. It became evident that there was a
need for a streamlined process which would not only identify CBU but also outline a well-defined
patient-centric follow up plan for affected patients. A story was shared by the DNP student of
several patients who had legitimate chronic pain issues and had to give up their pain contracts
and opioid therapy because they felt that their anxiety concerns and need for benzodiazepine
use was much more weighted. These were patients who not only could have been identified
with the proposed intervention, but with a well-documented follow up plan, they would have
maintained their therapeutic relationship with the providers within reasonable accommodation
and utilized a referral to the inhouse pain psychotherapist or an external psychotherapist for
follow up.
The second step in Kotter’s change model involves the selection of a strong team of
individuals who can guide change (Melynk & Fineout-Overholt, 2015). The DNP student
facilitator identified a medical assistant champion who had a vast knowledge of the processes,
respect and trust with other staff and was vested in the outcomes of the project with regards to

CONCURRENT BENZODIAZEPINE-OPIOID SCREENING

8

the utility of both the PDMP and the UDS in the identification on CBU. The medical assistant
champion was also the head medical assistant at the clinic setting
Step three entails the creation of a vision and realistic implementation strategy for
bringing the vision to fruition (Melynk & Fineout-Overholt, 2015). Per the stipulation of the
project, the idealistic timeframe for the project implementation was 90 days. To allow for ease of
documentation, an already existing auto-text quick step option in the electronic medical record
was utilized to aide with the quick download of the triad for documentation into patient charts.
The vision for the project was discussed with the providers and the support staff.
Step four necessitates communicating the vision (Melynk & Fineout-Overholt, 2015).
This was done through sharing the heartfelt stories of patients, the same stories that were
shared to communicate the sense of urgency and the need to go beyond “just abiding with the
guidelines” but including individualized patient outcomes which would ultimately improve safety
outcomes but also promote retention and patient satisfaction within the operational context.
Step five involves staff empowerment for behavioral change and elimination of barriers
that inhibit successful change (Melynk & Fineout-Overholt, 2015). The project did not require
any financial commitment or additional staff hours for implementation, the use of the auto-text
option also made the adaptation of the quarterly triad tool into routine EMR documentation
made it much easier for the providers to incorporate it.
Step six emphasizes the importance of celebrating short-term successes. Biweekly data
sharing sessions were planned to demonstrate compliance with use of the quarterly triad tool
and to further motivate the providers and staff to move toward Kotter’s seventh step of change.
Step seven highlights ongoing persistence needed to make the vision a reality. Initially,
not all providers were on board, in fact, only two out of four providers were willing to be a part of
the project, with the attitude of aiding the DNP student in seeing the project to completion rather
than changing practice outcomes. However, the DNP student planned persistence to making
the vision a reality and cementing the practice change. This stage of the change process was
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supported by the initial timeframe of piloting the change. Because the implementation time was
limited to 90 days, the DNP student was able to convince more providers to become part of the
project.
Step eight, which is the last step, highlights the necessity for nourishment of the new
culture to make it last. Melynk and Fineout-Overholt (2015), stipulated that it is important to
nourish the new culture to make the change last even if the leadership experiences transitions.
This nourishment is essential if the new culture and behavior are to be sustained (Melynk &
Fineout-Overholt, 2015). The DNP student developed a plan for sustaining the practice change
but buy in for the continued change by other prescribing providers was determined to be more
likely if the practice change was streamlined, was easily incorporated into current practice
change, resulted in positive outcomes, and did not negatively impact the flow of patient care
within the clinic setting.
Strengths and Limitations of Theoretical Framework for EBP Project
The main strength of the Kotter model for this EBP was that it maps out key steps and
components that are necessary for change. The model also addressed the emotional imperative
of change by ascertaining that there is a seeing and feeling and changing pattern necessary for
behavioral modification. This was very clear in the project implementation, as the DNP student
facilitator was able to use each aspect of the model as stipulated in the application segment of
this chapter.
A limitation of using the Kotter model was hat the assumption that positions change with
the successful transition from one step to the next may not be idealistic. At times, the vision
could precede the communication of urgency, and the process of communicating the vision
might overlap with the communication of the sense of urgency. Furthermore, it was noted that a
few of the steps overlap. There was also the insinuation of the trickle-down change aspect in the
selection of the leadership team. While this was in itself a strength with regards to steering of
goals and the vision, it could also be viewed as a weakness in that it was exclusionary, and
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those employees who were not included in the leadership team could view themselves as
puppets and become detached as they feel less ownership.
Evidence-based Practice Model
Early in the EBP movement, healthcare scientists, including many nurse scientists
developed models to organize our thinking about EBP and understand how various aspects of
EBP work together to improve care and outcomes (Melynk & Fineout-Overholt, 2015). These
models guide the design and implementation of approaches intended to strengthen evidencebased decision making and help clinicians implement an evidence-based change in practice
(Melynk & Fineout-Overholt, 2015). To facilitate evidence translation into clinical practice within
this DNP project, the PARHIS model was incorporated. The DNP student facilitator used the
PARIHS model to facilitate practice change by incorporating research evidence in the pain
management context, and utilizing already existing components of the culture, structure,
resources and the clinical staff to implement change.
Overview of EBP Model
The PARIHS (Promoting Action on Research Implementation in Health Services)
framework was used in the design and implementation of this EBP project. The PARIHS
framework posits an outline for evidence implementation. It is comprised of three interacting
core elements: evidence (E) ‘codified and non-codified sources of knowledge’ as perceived by
core stakeholders; context (C) the quality of the environment or setting in which the research is
implemented; and facilitation (F) a ‘technique by which one person makes things easier for
others,’ achieved through ‘support to help people change their attitudes, habits, skills and ways
of thinking and working’ (Helfrich et al., 2010). An integral component of the PARIHS framework
is the assumption that successful implementation of evidence is a function on these three key
components, where each factor can be rated on a scale from high to low and where high ratings
are likely to produce successful implementation results.
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In the PARIHS framework, evidence consists of four sub-elements, corresponding to
four main sources of evidence: (a) research evidence from studies and clinical practice
guidelines including, formal experiments; (b) clinical experience or related professional
knowledge; (c) patient preferences and experiences; and (d) locally derived information or data,
such as project evaluations of quality improvement projects. (Helfrich et al., 2010). The PARIHS
model argues that all of these four sources are equally weighted as sources of evidence.
Context comprises of sub-elements of organizational culture, leadership and evaluation.
Culture creates the context for practice, character and feel of the physical environment; effective
leadership provides clear roles, effective teamwork and effective organizational structures; and
evaluation refers to the types of measurement tools and methods for reporting used by the
organization (Stetler et. al., 2011).
Application of EBP Model to EBP Project
The PARIHS EBP model was ideal because it allowed for the translation of theoretical
knowledge to practice. By understanding the context of the organization, the DNP student
facilitator was able to determine the most appropriate method to improve practice at the pain
clinic. The need for the EBP project was ascertained following discussion with the administrator.
Education was provided to prescribing providers and supportive staff. A champion medical
assistant was identified to help with the roll out process, data collection and the education of
other supportive staff with regards to project goals and outcomes. The DNP facilitator also
discussed components of the electronic medical record (EMR) with the information technology
staff, and then created the auto text component specific the quarterly triad tool which prompted
allowed providers to download all the components of the tool within their clinic visit notes within
seconds. The auto-text component was also used by the staff at the clinic routinely for
documentation of other components of care.
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Strengths and Limitations of EBP Model for EBP Project
The main strength of the EBP model was the fact that the DNP student facilitator was
also part of the staff at this clinic with established credibility and authority within the
organization. Secondly, the DNP student understood the EMR which allowed for easy
navigation, creation and inclusion of the QTT within the charting system. Given that the project
did not require any funding or additional staffing hours for implementation, it was well accepted
by both leadership and staff. The model provided preliminary measure of evidence and context,
and the use of the most appropriate methods of implementation. The limitation of the framework
was the inability to assess how each of the elements of the framework impacted the
implementation of the project as it appeared that facilitation took precedence over evidence and
context.
Literature Search
Sources Examined for Relevant Evidence
An extensive literature search was conducted using multiple databases including
CINAHL, Cochrane Library, Science Direct, ProQuest, and MEDLINE (EBSCO host). Additional
literature was also obtained from a hand search and citation chasing. The purpose of the
literature review was to uncover evidence that supported the most effective approach of
evaluating at risk patients for CBU. Results were compiled and the best interventions were
included in the design of the evidence-based project (EBP). Interventions which included a
routine review of urine drug screens (UDS) and prescription drug monitoring programs (PDMP)
to assess for concurrent benzodiazepine use (CBU), were used to create the quarterly triad tool
(QTT), which was implemented in the project.
Search terms included Opioid* AND Prescriber OR Prescription AND PDMP OR
“Prescription Drug Monitoring Program” OR Urine Drug Screen OR Benzodiazepines and
chronic pain. The numbers of results found in each database can be found in Table 2.1.
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Inclusion criteria for the literature search encompassed publications from 2012 to
present to accommodate the dynamic nature of this project and include the most up to date
information. The publications had to be in English language, scholarly or academic journals, and
peer-reviewed journals covering outpatient adult populations. Inpatient, pediatric, studies of
dental providers were excluded. Articles that did not address concurrent benzodiazepine use
were also excluded.
The initial literature search yielded 104 relevant articles, of which 35 were duplicates and
32 did not fit the inclusion criteria. A review of the remaining 37 abstracts resulted in seven
articles being deemed worthy of further review based on inclusion criteria. Four of the seven
articles that were selected for review were from a hand search and one was obtained from
citation chasing. After reviewing a full text of the seven articles, the DNP student determined
that all seven met both inclusion and exclusion criteria based on the level and the quality of
evidence. Results are as listed below (Table 2.1.)
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Table 2.1
Literature Search
Database

Duplicates

Cochrane

Articles
Found
12

0

Abstracts
Read
12

Applicable
Articles
0

CINAHL

34

0

14

1

ProQuest

40

25

0

0

Science
Direct
Medline
EBSCO
Host
Hand
Search
Total

10

6

4

1

8

4

4

0

5

0

3

5

109

35

37

7
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Table 2.2
Evidence Table
CITATION

CENTERS
FOR DISEASE
CONTROL
AND
PREVENTION
(2016)

DOBSCHA, S.
K. (2013)

DESIGN/
LEVEL/
QUALITY
RATING
Clinical
practice
guideline
Level IV
High
quality

SETTING/SAMPLE/
TARGET GROUP

INTERVENTION/
RECOMMENDATIONS

OUTCOMES/
MEASURES

Primary care
clinicians who are
prescribing opioids
for chronic pain
outside active
cancer treatment,
palliative care, and
end of life care

Recommends routine
assessment for patient risk and
addressing harms of opioid use
through (a) review of PDMP
data to identify opioid dosages
or dangerous combinations
linked to risk for overdose, (b)
urine drug testing before
starting opioid therapy and then
at least annually to assess for
prescribed medications, other
controlled prescribed drugs and
illicit drugs, (c) avoidance of
concurrent prescribing of
benzodiazepines and opioids

Expert
opinion
Level V
High
quality

Clinicians caring for
patients impacted by
CBU

Recommends moving beyond
“just say no” where providers
should outline an “exit strategy
for the discontinuation of
concurrent benzodiazepineopioid use

Guideline is intended
to improve
communication
between clinicians
and patients about
risks and benefits of
opioid therapy for
chronic pain, improve
safety and
effectiveness of pain
treatment and reduce
the risks associated
with long-term opioid
therapy, including
opioid use disorder,
overdose and death
Exploring follow up
plans for patients on
CBU while reducing
anxiety and limiting
recurrent use:
communication with
patients; gradual dose
reductions; medication
substitute; CBT;
clinician education and
feedback; monitoring;
and system support.

FINDINGS

CONCURRENT BENZODIAZEPINE-OPIOID SCREENING
GEORGE,
2018

Expert
opinion
Level V
Good
quality

GUDIN, J. A.,
MOGALI, S.,
JONES, J. D.,
& COMER, S.
D. (2013)

Expert
opinion
Level V
High Quality
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Patients on opioid
and benzodiazepines
as evaluated from
urine drug screens

Clinicians need to be aware of
their patients are taking are
using potentially dangerous
combinations of drugs:
benzodiazepines and opioids.
State based PDMP are limited
to prescribed drugs; therefore,
a more effective detection of
drug use is achieved by
supplementing the prescribed
database information with UDS

Patients on CBU

Chronic pain patients
taking opioids and
benzodiazepines
concurrently require
routine monitoring for
aberrant drug
behaviors, treatment
compliance,
documentation of
medical necessity and
the adjustment of
treatment to clinical
changes are essential.
Patients receiving COT
should periodically
undergo urine drug
testing to confirm
adherence to the
treatment plan

Non-prescribed
CBU cannot be
determined by
PDMP alone.

Routine
monitoring for
compliance and
aberrant
behavior to
mitigate risks

Urine drug
screens of patients
on opioids were
reviewed, 68.2%
of specimens
tested positive for
opioids, 20.6% of
specimens tested
positive for CBU.
Of these patients,
36% had been
prescribed both
drug classes and
64% had at least
one nonprescribed drug
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HAWKINS, E.
J., MALTE,
C.A.,
GROSSBARD,
J. R. (2015)

Retrospective
research
study
Level III
Good quality

Patients with posttraumatic stress
disorder at a veteran’s
affairs clinic on CBU

MCCLURE, F.
L., NILES, J.
K., KAUFMAN,
H. W., &
GUDIN, J.
(2017)

Qualitative
Level III
High quality

Patients on concurrent
opioid-benzodiazepine
use identified from
urine specimens that
tested positive for both
medications

OREGON
HEALTH
AUTHORITY
PUBLIC
HEALTH
DIVISION.
(2016)

Clinical
Practice
guideline
Level IV
High quality

All clinicians
prescribing opioids in
Oregon
Task force endorsed
CDC guidelines as
stated above

17
Concurrent use was
identified as periods of
overlapping opioid and
benzodiazepines
prescriptions for 90
days or more
consecutively. Genderspecific logistic
regressions estimated
long-term concurrent
use of these
medications and tested
for linear trends over 9
years
The urine specimens
that were prescribed
either an opioid or a
benzodiazepine were
tested for both
medications

Same as those
recommended by the
CDC since the adopted
the CDC guidelines

The use of
comprehensive
strategies to
identify and
monitor patients
on chronic
opioid and
benzodiazepines
for adverse
outcomes

A high
prevalence of
concurrent use
was noted,
particularly nonprescribed use.
This suggested
the need for
more effective
clinician
assessment and
intervention
To provide
additional clarity
to the CDC
guideline and to
address Oregon
specific issues

Despite known risks
associated with
concurrent opioid and
benzodiazepine use, the
adjusted prevalence
rose significantly among
these patients over a 9year period. This
common use suggests
that comprehensive
strategies are needed to
identify and monitor
patients as risk for
adverse outcomes
Results supported the
CDC guideline that drug
testing should occur
before and periodically
throughout opioid use
and suggest that this
testing should be
extended to patients
prescribed
benzodiazepines as well
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Levels of Evidence
A total of seven sources of evidence were deemed worthy of inclusion into the literature
supporting this EBP, which included two descriptive studies, three expert opinions, and two
clinical guidelines. After obtaining permission for use, these sources were appraised using the
Johns Hopkins Research Evidence Based Practice Appraisal tool. Evidence was ranked from
level I through level V, with level one being representative of the highest level of evidence and
level V the lowest (Dearholt & Dang 2014). The literature search did not yield any randomized
control studies, experimental or quasi-experimental studies, which would have been considered
level I and II levels of evidence. This was attributed to the likelihood of the ethical nature of
selective screening for patients who were on concurrent benzodiazepine-opioid use; providers
could not compromise patient safety by screening a specific set of patients over the others. It
however yielded two level III research studies; (Hawkins et al., 2015; McClure, Niles, Kaufman,
& Gudin, 2017), two level IV clinical practice guidelines from the CDC and Oregon Chronic
Opioid Prescribing guidelines, and three level V expert opinions (Dobscha, 2013; George, 2018;
Gudin, Mogali, Jones, & Comer, 2013).
Appraisal of Relevant Evidence
Construction of Evidence-based Practice
Level III Evidence
Hawkins et al. (2015) examined the trends in annual prevalence of long-term concurrent
opioid and benzodiazepine use among patients with posttraumatic stress disorder (PTSD) and
prevalence of high-risk conditions in concurrent users of these medications. The researchers
conducted a retrospective review of pharmacy records of patients at a Veteran’s Affairs clinic.
Concurrent use was defined as overlapping opioid and benzodiazepine prescriptions for at least
90 consecutive days. Gender-specific logistic regressions estimated long-term concurrent use of
these medications and tested for linear trends over nine years. The researchers found that,
despite known risks associated with prescribing opioids and benzodiazepines concurrently, the
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prevalence of long-term concurrent use rose significantly among men and women with PTSD
over a 9-year period. The researchers concluded that comprehensive strategies were needed to
identify and monitor patients at increased risk for adverse outcomes.
After permission for use was granted (see Appendix A), this article was evaluated using
the Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool and
found to be of good quality. The study supported the necessity for comprehensive monitoring
strategies to reduce CBU use, which was the premise behind the creation of the QTT.
McClure, Niles, Kaufman, and Gudin, (2017), analyzed CBU prescription patterns in the
context of urine drug testing results and found CBU in 25% of opioid prescribed patients. In 52%
of those with evidence of CBU, one drug class was prescribed, while the other was nonprescribed. Nearly one of five specimens testing positive for prescribed opioids also tested
positive for non-prescribed benzodiazepines. While more than 15% of those who were
prescribed benzodiazepines also had evidence of non-prescribed opioid use. The researchers
concluded that the extent of CBU and opioids, particularly the non-prescribed use, reflected the
need for more effective clinician assessment and intervention. The researchers’ findings
supported the CDC guideline that drug testing should occur before and periodically throughout
opioid use and suggested that this testing should be extended to patients prescribed
benzodiazepines as well.
This research article was also found to be of high quality. The evidence supported the
use of urine drug screens (which are a component of the QTT) to evaluate for prescribed and
non-prescribed CBU periodically throughout opioid use.
Level IV Evidence
Clinical practice guideline from the CDC recommend for clinicians to review the history
of controlled substance prescription using the states prescription drug monitoring program
(PDMP) data to determine whether the patient is receiving opioid dosages or dangerous
combinations that put the patient at risk for overdose. The guideline recommends for clinicians
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to use PDMP at the initiation of opioid therapy and then periodically during opioid therapy
ranging from every prescription to every 3 months. The guidelines also recommend the routine
assessment of urine drug screens to assess for prescribed medications as well as other
controlled prescription drugs and illicit drugs. Finally, the guidelines recommend the avoidance
of concomitant prescribing of benzodiazepines and opioids whenever possible.
According to the John Hopkins Nursing Evidence-Based Practice Research Evidence
Appraisal Tool, this research article was of high quality. The QTT encompasses all the
recommendations of the CDC guideline in one routine assessment.
Clinical guideline from the American Academy of Pain Medicine and Oregon Chronic
Opioid Prescribing guidelines reinforce the avoidance of concurrent benzodiazepine-opioid
prescribing, routine use of PDMP and periodic assessment of urine drug screens. Both sources
of evidence were rated as high-quality evidence per John Hopkins Nursing Evidence-Based
Practice Research Evidence Appraisal Tool
Level V evidence by alphabetical order
Steven K. Dobscha, MD is a Doctor at the Center to Improve Veteran Involvement in
Care (CIVIC) at the Veterans Affairs Medical Center in Portland Oregon. He has 31 years of
experience. His specialties include; Psychosomatic Medicine, Clinical Informatics, Psychiatry
and Neurology. His body of work entails approaches to integrating psychiatric and primary
medical care and managing chronic conditions including chronic pain in primary care. According
to Dobscha (2013), multiple studies have shown that patient with psychiatric conditions are
more likely to be prescribed opioids than patients without psychiatric conditions. He noted that
psychiatric disorders (i.e., anxiety and post-traumatic stress disorders) are strongly associated
with opioid prescriptions. He noted that the increase in CBU prescription patterns could be
attributed the fact that chronic pain and anxiety are comorbid. He argues that several
interventions have been shown to be effective in increasing rates of benzodiazepine
discontinuation while reducing anxiety and limiting recurrence of use, he listed follow up
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examples like writing letters to patients explaining necessity for discontinuation, use of
structured gradual dose reduction programs, prescription of substitute medication and
psychological treatment considerations like cognitive behavioral therapy. He also suggested that
interventions that are likely to change clinician behavior and result in improved patient outcomes
should involve: clinician education, feedback and monitoring, and system support. These
interventions go beyond the guidelines.
According to the John Hopkins Nursing Evidence-Based Practice Research Evidence
Appraisal Tool, this research article was of high quality. The first step of the QTT would be
identification of CBU through screening. Then, providers can undertake individualized or
system-wide follow up plans to reduce CBU. Like the recommendation by Dobscha the QTT
involves clinician education of the indication and benefit of using the QTT, its inclusion in the
EMR allows for feedback and monitoring of identified patients and its ease of use through the
recommended auto-text quick chart option allows for an easy incorporation into routine
documentation
Jeffrey Gudin, MD, is a director of pain and palliative care at Englewood Hospital AND
Medical Center in New Jersey. He is board certified in pain medicine, anesthesiology, addiction
medicine and hospice/palliative medicine. Dr. Gudin’s clinical and research focus includes postoperative pain management, opioid abuse and potential solutions, and increasing clinician
awareness of pain assessment and risk management. In a published article that serves as an
expert opinion. Gudin et. al., (2013) opined that in order to improve patient outcomes for chronic
pain patients taking opioids and benzodiazepines concurrently, routine monitoring for aberrant
drug behaviors, treatment compliance, documentation of medical necessity and the adjustment
of treatment to clinical changes are essential. They stated that regardless of the risk of risk or
known aberrant drug-related behaviors, patients receiving COT should periodically undergo
urine drug testing to confirm adherence to the treatment plan.
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According to the John Hopkins Nursing Evidence-Based Practice Research Evidence
Appraisal Tool, this research article was of high quality, it supported the periodic use of urine
drug screens to confirm adherence to the treatment plan.
Judy George is a freelance journalist and a contributing writer for MedPage today, an
online clinical website which covers both clinical and policy issues that impact healthcare
professionals. Her article is a review of a poster presented at the pain week by L. McClure and
colleges. The data summarized from the poster indicated that among a selected sample of
patients whose drug test indicated concurrent benzodiazepine and opioid use, 64% had at least
one benzodiazepine or opioid that was not prescribed. These findings supported the use of a
UDS in addition to PDMP to evaluate for CBU.
According to the John Hopkins Nursing Evidence-Based Practice Research Evidence
Appraisal Tool, this research article was of good quality, it supported the additional use of a
urine drug screen in addition to PDMP review to evaluate for non-prescribed use.
Synthesis of Critically Appraised Literature
A major theme which was identified in the literature review was the formidable challenge
faced by clinicians of concurrent benzodiazepine-opioid use among patients on chronic opioid
therapy (CDC, 2016; Dobscha, 2013; George, 2018; Gudin, Mogali, Jones, & Comer, 2013;
McClure, Niles, Kaufman, & Gudin, 2017; Oregon Health Authority Public Health Division,
2016). The majority of evidence for this EBP project stemmed from expert opinion and clinical
practice guidelines. These experts identified the need for screening (Dobscha, 2013; Hawkins et
al., 2013) and intervening (CDC, 2016; George, 2018; Gudin, Mogali, Jones, & Comer, 2013;
McClure, Niles, Kaufman, & Gudin, 2017; Oregon Health Authority Public Health Division, 2016)
to address CBU. Some of the evidence reviewed focused on the use of both UDS and PDMP
(CDC, 2016; George, 2018; Hawkins et al., 2013; and Oregon Chronic Opioid Prescribing
guidelines;) while others focused on the use of UDS independently (Gudin, Mogali, Jones, &
Comer, 2013; McClure, Niles, Kaufman, & Gudin, 2017). Both CDC and Oregon guidelines
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recommended the review of PDMP at the initiation of opioid therapy and then periodically
throughout opiate therapy. CDC and Oregon guidelines recommended screening every 3
months (CDC, 2016; Oregon Health Authority Public Health Division, 2016)
Best Practice Model Recommendation
Consistent with the PARIHS model, the EBP project was facilitated by the utilization of
appraised literature (evidence), to promote a recommended practice change at the pain clinic
(context) the through the use of the QTT (mechanism). The DNP student presented the
evidence to the providers at the facility, and it was determined that the best practice
recommendations were applicable to the project with regards to the creation and utility of the
QTT for risk assessment and mitigation. The evidence review highlighted best practice
recommendations that were needed to answer the PICOT question: Among pain management
providers (P), does the use of a standardized quarterly triad tool (QTT) consisting of PDMP,
UDS, and medication reconciliation for CBU (I), compared to the current practice of PDMP or
UDS only (C), increase the monitoring of CBU and providers initiation of a benzodiazepine
specific follow up plan (O) over a 90-day period (T)?
How the Best Practice Model Will Answer the Clinical Question
Evidence from the literature synthesis provided the foundation for the creation of the
quarterly triad tool (QTT). The operational plan entailed provider and support staff education on
the utility and necessity of the QTT. It was agreed upon by the DNP student facilitator and
clinical leadership that the QTT, comprising of; an evaluation of the prescription drug monitoring
program, urine drug screen and concurrent benzodiazepine use assessment from the
medication reconciliation would be uploaded in patients’ electronic monitoring record. This
would be done in a quick chart format also known as auto text. Providers would then evaluate
patients on chronic opioids seen monthly at each of their third visit for concurrent opioid and
benzodiazepine use using all the three parameters. The DNP student facilitator was selected as
the clinical champion for the providers and the lead medical assistant was identified as the
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clinical champion for the supportive staff. A power point presentation created by the DNP
student was used for one-on-one education session with the providers and the support staff.
The PARIHS model incorporates evidence, context and mechanism by which change is
facilitated as key variables in the translation of research into practice. The context was ideal
given that providers saw a large volume of patients with chronic pain on opioids who were seen
routinely (monthly), for follow up visits. It was therefore imperative to ensure that chronic opioid
prescribing was done within the appropriate safety guidelines. The research evidence, both
contextual and theoretical as discussed in chapters one and two was strong enough to justify
the necessity for the project implementation with regard to risk, impact and recommendations
for intervention. Additionally, the DNP student and the facility leadership engaged in careful
planning of the intervention and its components (use of QTT), staff involvement and the
incorporation of the intervention into charting and routine practice. Finally, an audit and
management of project outcome would be attained through the data collection process.
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
The CDC has recommended avoidance of concurrent prescribing of opioids and
benzodiazepines as a risk mitigation strategy in patients on chronic opioid therapy (CDC, 2016).
However, evidence has noted that 30% to 40% of patients prescribed long-term opioids are also
prescribed benzodiazepines (Dobscha, 2013). Even more concerning is the statistic that 65.8 %
of patients prescribed long-term opioids are taking benzodiazepines from non-prescription
sources (McClure et al., 2017). Concurrent use of benzodiazepines is likely to put patients at
greater risk for hospitalization and potentially fatal overdose (CDC, 2016) Practices often use
PDMP regularly to evaluate for concurrent use of prescribed medications which may increase
risks associated with COT, but this strategy fails to capture and address those who may be
using benzodiazepines not obtained via a prescription. Therefore, state and national guidelines
now recommend the routine use of PDMP and UDS to evaluate risk in patients on COT.
This chapter will describe the methods used to answer the following PICOT question:
Among pain management providers in an outpatient clinic, does the use of a standardized
quarterly triad tool with concurrent benzodiazepine use (CBU) assessment, promote provider
adherence to the monitoring and decrease of CBU, compared to the current practice of not
using the quarterly triad tool, within a 90-day period? A single group pre- and post-intervention
analysis was used to address the purpose of this project. In this section, details about the
participants, setting, planning, evidence implementation, anticipated outcomes, and human
rights protection considerations planned for the project will be described.
Participants and Setting
The project was initiated in a specialty pain clinic setting, where prescribers were vested
in a multi-disciplinary team approach in improving patient safety outcomes, with CBU being one
of the key markers, with regards to chronic opioid prescribing. One of the unique features of the
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setting for this EBP project is that both administrators and clinical staff (key stakeholders) were
proactive about preventing CBU within the patient population. Both groups of stakeholders had
identified safe opioid prescribing, including the avoidance of CBU, as a high priority initiative to
combat the local opioid epidemic. Strategies that were in use at the time this project was
implemented included (a) adoption of a shared value system in which CBU was discouraged,
(b) avoidance of prescribing benzodiazepines to patients on long-term opioid therapy, (c)
initiation of an opioid weaning goal of less than 90 morphine milligram equivalents (MME), (d)
the opportunity for patients to prioritize either their pain or their anxiety as their treatment goal,
and (e) the implementation of a therapeutic interchange program, which entails changing from a
benzodiazepine to a non-benzodiazepine for anxiety management.
The provider participants in this EBP project included all prescribers of chronic opioids
who completed routine quarterly visits at the pain clinic in the Midwestern United States. The
clinic had been in existence for past 17 years. Patients were self-referred or referred by PCPs
for management of chronic pain. The make-up of provider staffing on a typical Wednesday (the
day selected to obtain baseline data) included three physicians, two physician assistants (PAs),
and a nurse practitioner (NP). Of the three physicians, one was relatively new to the clinic,
having been at the clinic since December of 2018, but also having more than three years of
experience in pain management. The other two physicians both had more than 10 years of
experience in chronic pain management and had been at the clinic for more than five years.
One of the two PAs had more than 10 years of PA experience and had been at the clinic for
more than five years, and the other had three years of experience and had been at the clinic for
three years. The NP, the DNP student facilitator, had worked at the pain management clinic for
more than a year. Apart from the NP, who worked part time (3 days a week), all the other
providers were full time. Each provider had a separate panel of patients whom they cared for
routinely and saw an average of 18 to 25 patients on a Wednesday.

CONCURRENT BENZODIAZEPINE-OPIOID SCREENING

27

Other key stakeholders and project participants included all medical assistants (MAs)
who assisted in the patients’ “rooming process” as well as the compliance registered nurse (RN)
who selected patients randomly for the evaluation of quarterly baseline data. The clinic
administrator was the DNP student’s project facilitator at the site.
Patients, of all providers, who were being seen for their quarterly visit were the target of
the change in provider behavior. Because the project design included a systematic change
within the entire clinic, patients seen by the DNP student were included in the project. The
inclusion criteria for patients was all adult patients over the age of 18 on long-term opioids under
the supervision of clinician, who were seen for quarterly visits on Wednesdays. There were no
additional exclusion criteria for providers or patient participants.

Pre-implementation Data
The clinic providers were already screening for illicit drugs like cocaine, heroin,
methamphetamines, and other opioids not otherwise prescribed at the pain clinic) by
discretionary random UDS. Some incidental CBU through random UDSs and patients’ reports
during medication reconciliation patterns were also identified.
The pre-implementation data was evaluated in August of 2018. The clinic support staff
provided data on all quarterly visits done on Wednesdays for a 12-week period. Total patient
numbers of quarterly assessments ranged from 8 to 20 each Wednesday. Pooled total data
from four Wednesdays of quarterly visits yielded a sample size of 52. Twenty of these patients
(38%) were found to have been on both benzodiazepines and opioids. 5%) had patient specific
follow up plans documented within the electronic charting. Education for patients on CBU also
included risks associated with other non-benzodiazepine medications (e.g., muscle relaxants,
sedative hypnotics, and alcohol) which presented the risk of central nervous system depression

Although providers had documented a review of PDMP, of the 52 reviewed charts, none of the
providers had specifically documented that they specifically screened for CBU. In 3 of 20 charts
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where CBU was identified, opioid therapy wean was initiated. In the remaining 17 charts, no
interventions were documented.
Outcomes

The primary outcome of the EBP project was the standardization and intensification of
provider adherence with CBU screening. Compliance was defined as a ratio of the number of
times in which providers used the QTT to the number of times CBU was identified. Other
additional goals included the number of times CBU was identified and the number of times risk
education was performed and finally the number of times CBU was identified and the number of
times follow up education was initiated. For the purpose of this project, QTT should have been
used by each participant at every quarterly visit to be in alignment with the CDC
recommendations (CDC, 2017). Data to calculate this compliance ratio was retrieved from
patients’ medical records.
It was anticipated that as an added benefit, use of the QTT would result in
standardization of provider documentation with its inclusion in the electronic medical record
(EMR). The inclusion in the EMR would also simplify the screening process through the use of
the auto text application which copied and pasted the tool to the patients’ visit note. This
process was streamlined to minimize effort and improve compliance.
Intervention
In the pre-implementation phase, the DNP student facilitator evaluated the clinic for
project preparedness by establishing provider and staff buy-in, consistent with Kotter’s change
model. Then, the project facilitator collected data about the provider compliance with the use of
the QTT inclusive of all three components: prescription drug monitoring program, urine drug
screen, and a review of the medication reconciliation. CBU identification as well as providerpatient education patterns and follow up planning if CBU was identified, was completed using a
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data collection tool (Appendix B). The DNP student facilitator also procured educational
materials and developed a face-to-face education plan for the prescribing providers.
Following approval by the Institutional Review Board at Valparaiso University,
implementation of the project began in September 2018. Implementation included a formal 30minute face-to-face education sessions from September 1st-3rd and the identification and
appointment of a clinical champion. Education was delivered using a face-to-face approach
scheduled at convenient times for each provider over a 3-week period of time. Each prescribing
provider was educated separately. Education included the following topics: best practice for
chronic opioid prescribing, need for elimination of concurrent benzodiazepine use through
individualized follow up plans for patients and utility of the quarterly tried tool. Lecture slides and
the CDC Guideline for Prescribing Opioids for Chronic Pain (Appendix C) were provided to clinic
staff. During this phase, the quarterly triad tool (Appendix E) was implemented. The triad tool
consisted of a quarterly PDMP and UDS with specific instructions to monitor both for evidence
of CBU. Furthermore, the combined approach using the PDMP and UDS would assist providers
in identifying both prescribed and unprescribed or illicit benzodiazepine use. The PDMP would
identify prescribed medications while the UDS would detect non-prescribed medications or illicit
drug use. Providers were instructed to educate patients on risks and discuss a plan for
discontinuation of concurrent opioid and benzodiazepine use if CBU was identified.
Planning
In the pre-implementation phase, the DNP student facilitator evaluated the clinic for
project preparedness by establishing provider and staff buy-in, consistent with Kotter’s change
model. Then, the project facilitator collected data about the provider compliance with the use of
the QTT inclusive of all three components: prescription drug monitoring program, urine drug
screen, and a review of the medication reconciliation. CBU identification as well as providerpatient education patterns and follow up planning if CBU was identified, was completed using a
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data collection tool (Appendix B). The DNP student facilitator also procured educational
materials and developed a face-to-face education plan for the prescribing providers.
Following approval by the Institutional Review Board at Valparaiso University,
implementation of the project began in September 2018. Implementation included a formal 30minute face-to-face education session from September 1st-3rd and the identification and
appointment of a clinical champion. Education was delivered using a face-to-face approach
scheduled at convenient times for each provider over a 3-week period of time. Each prescribing
provider was educated separately. Education included the following topics: best practice for
chronic opioid prescribing, need for elimination of concurrent benzodiazepine use through
individualized follow up plans for patients and utility of the quarterly tried tool. Lecture slides and
the CDC Guideline for Prescribing Opioids for Chronic Pain (Appendix C) were provided to clinic
staff. During this phase, the quarterly triad tool (Appendix D) was implemented. The triad tool
consisted of a quarterly PDMP and UDS with specific instructions to monitor both for evidence
of CBU. Furthermore, the combined approach using the PDMP and UDS would assist providers
in identifying both prescribed and unprescribed or illicit benzodiazepine use. The PDMP would
identify prescribed medications while the UDS would detect non-prescribed medications or illicit
drug use. Providers were instructed to educate patients on risks and discuss a plan for
discontinuation of concurrent opioid and benzodiazepine use if CBU was identified.
Data
This EBP project measured provider compliance with monitoring CBU. Data was
measured as a ratio, which allowed for compliance to be analyzed as a continuous variable. It
also measured compliance/adherence rates per provider. The end data compared the number
of times that provider used QTT to screen for CBU, and if CBU was identified, further steps
were taken to determine if (a) risk education was provided and (b) an individualized plan of care
was initiated for the patient.
Measures
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Chi square analyses were used to evaluate provider adherence rates. Descriptive
statistics were used to document information pertaining to risk education and follow up plans for
patients who screened positive for concurrent benzodiazepine-opioid use.
Collection
Data collection was initiated one month following the launch of the intervention. The
compliance registered nurse identified patients who would be coming in for the 3rd month visit of
the year also known as the quarterly visit each Wednesday. The MA champion printed out a
quarterly visit summary, designating each patient to their assigned provider on Tuesday
evening. Random sampling of patients was completed until at least 20 patients identified to be
on CBU were seen. Data evaluating provider adherence to screening using the quarterly triad
tool was obtained within 12-week timeframe between October 2018 and December 2018. The
DNP project facilitator collected data using a chart audit process with a standardized data
collection form (Appendix E). Specific evaluative data collected included (a) if the QTT was
used, (b) if CBU was identified, (c) whether patient risk education was documented if CBU was
identified, and (d) if an individualized follow up plan was identified.
Management and Analysis
The DNP student collected the data through a chart audit process and recorded it in a
Microsoft Excel spreadsheet. IntellectusStatisticsTM software was used for data analysis. To
analyze the main outcome of this project, the use of the QTT with all the three components
(UDS, PDMP and medication reconciliation to screen for CBU) was coded as “QTT yes” or
“QTT no” for each provider. Screening for CBU was coded as “CBU yes “or “CBU no”. Risk
education documentation was coded as “RE yes” or “RE no” and follow up education was coded
as “FU yes” or “FU no”. Compliance with these components was calculated as percentage.
Descriptive statistics were used to determine if providers who used the quarterly triad
tool were effective at educating patients on risks for CBU and initiating follow up planning, a chi-
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square analysis was performed to compare the pre and post QTT implementation follow up
planning.
Protection of Human Subjects
The DNP student completed human rights training from the National Institutes of Health
(NIH) in April 2018 (Appendix F). The student then received the Institutional Review Board (IRB)
clearance from Valparaiso University in September 2018. Permission to use the clinical site was
provided by the administrator. The project was considered exempt for the institutional review
board because the information collected was de-identified and there was no patient interaction
or treatment that would have involved physical procedures by which data are gathered (e.g.,
venipuncture) and manipulations of the subject or the subject's environment that would be
performed for research purposes, therefore patient consents were not necessitated.
The DNP student had access to the EMR through authorization from her active
employment status at the clinic, and the initial audits were conducted in a closed office without
other staff members to ensure data protection. The DNP student gathered the data from the
printed quarterly visit summary in her office alone, deidentified, coded and recorded it on the
excel worksheet on the DNP student’s lap top which was password locked. This spreadsheet
was stored on the DNP student facilitator’s secure laptop, and no patient identifying information
was used or stored in compliance with HIPAA. The summary with patient identifying information
was stored in a designated locked cabinet, accessible by key to the MA champion and the DNP
student. The MA printed the upcoming quarterly visit summaries every Tuesday in her cubby
and then handed the summaries to the DNP student. For the provider coding, the three
physician providers were coded with the letter P before their designated number, the PA
providers were coded with the letter A before their designated number and the NP who was also
the student facilitator was coded with the letter SF, and because she was the only NP provider,
there were no numbers assigned to the SF code.
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The potential for selection bias was minimized given that the DNP facilitator was not
involved in the random patient selection process. But a plan was designed to evaluate
adherence to the systematic change with the DNP facilitator’s data both included and excluded
from final analyses.
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CHAPTER 4
FINDINGS
The purpose of this EBP project was to determine the effect of the utility of standardized
quarterly triad tool on provider adherence to screening for concurrent benzodiazepine-opioid
use, and its impact on risk education and follow up plans for identified patients. The QTT was
developed from evidence-based CDC guideline for prescribing opioids for chronic pain, (CDC,
2017). The PICOT question was: Among pain management providers in an outpatient clinic,
does the use of a standardized quarterly triad tool with concurrent benzodiazepine use (CBU)
assessment, promote provider adherence to the monitoring and decrease of CBU, compared to
the current practice of not using the QTT within a 90-day period? The project was conducted in
a pain clinic setting in Central Indiana.
Pre-implementation data was collected from four Wednesdays using a retrospective
chart review. A retrospective chart review was also used to collect post-implementation data 12
weeks after the initiation of the project to evaluate the effect of QTT use among six providers.
Data analyses were conducted using IntellectusStatisticsTM statistical software. Testing was
performed to answer the following primary question: Does provider education increase the use
of the QTT to monitor for CBU? Statistical analysis also evaluated the secondary questions:
Does adherence to QTT increase provider risk education documentation for patients on CBU?
and Does adherence to QTT increase provider follow up planning documentation for patients on
CBU?
Participants
Participants included six providers who worked on Wednesdays when data was
collected which comprised of three physicians, two physician assistants (PAs), and a nurse
practitioner (NP), who led the practice change. All patients on chronic opioid therapy who were

CONCURRENT BENZODIAZEPINE-OPIOID SCREENING

35

at the clinic for their third month visit on Wednesdays per the quarterly visit summary were
included in the data set.
Size and Characteristics
Pre-intervention group characteristics. Summation of data from six providers on four
Wednesdays of quarterly visits yielded a population of 52. Twenty of these patients (38%) were
found to have been on both benzodiazepines and opioids. Of these 20 patients, six were seen
by physicians, the remaining 14 were seen by advanced practice providers; 11 by one of the
two PAs and three by the NP. Of the 20 patients on CBU, only 25%, had risk education
documented and only 5% had patient-specific follow up plans documented within the plan of
care. The DNP student who was also the project facilitator saw three patients who were
identified to be on CBU, one of the three patients had risk education (33%) and follow up
planning (33%) documented.
Intervention group characteristics. Data was collected from the six providers on 12
Wednesdays of quarterly visits. One of the six providers did not adopt the QTT. Even with this
lack of buy-in, a total of 151 of 154 patients (98.05%) were screened. In 24 of 151 patients
(15.89%) who were screened, concurrent benzodiazepine use was detected. Of the 24 patients
who screened positive for CBU, the five remaining providers used the tool (100%) and all the 24
patients (100%) also had risk education documented. Of the 24 CBU patients, 18 (75%) had a
follow up plan documented. When follow up information was evaluated with the NP data
removed (7 CBU patients), a follow up plan was documented in 11 of the remaining 17 patients
(64.7%). Comparison data are included in Tables 4.1, 4.2, and 4.3.
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Table 4.1
Post QTT Intervention Evaluation of Practice Change Adoption
Provider QTT
Yes
Ph 1 0
Ph 2 12
Ph 3 12
APP 1 36
APP 2 48
APP 3 43
Total with 151
APP 3
Total with 108
APP 3
removed

QTT
No
3
0
0
0
0
0
3

CBU
Yes
0
2
1
7
7
7
24

CBU
No
0
10
11
29
41
36
127

Risk Ed
Yes
0
2
1
7
7
7
24

Risk Ed
No
0
0
0
0
0
0
----

Follow
Yes
0
1
1
2
7
7
18

Follow
No
0
1
0
5
0
0
6

3

17

91

17

----

11

6

Table 4.2
Provider Risk Education and Follow Up Post QTT Adoption
Provider
Ph2
Ph3
APP1
APP2
APP3
Total with APP3
Total with APP3 removed

% Risk education
100%
100%
100%
100%
100%
100%
100%

% Follow up
50%
100%
27%
100%
100%
75%
65%

Table 4.3
Comparison of Pre-Intervention and Post-Intervention Risk Education and Follow up Plan
Documentation
Risk Education
Pre-Intervention
(n = 20)
5 [25%]

Post-Intervention Analyses
(n = 24)
24 [100%]
X2 = 10.588
p =.001

Follow Up Plan Documentation
Pre-Intervention Post-Intervention Analyses
(n = 20)
(n = 24)
3 [15%]
18 [75%]
X2 = 8.235
p =.004
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Changes in Outcomes
Statistical Testing
Descriptive and inferential statistics were used to compare provider adherence. A Chisquare test was used to compare risk education and follow up planning for CBU post
implementation of the use of QTT. Statistical testing was completed using IntellectusStatisticsTM
software.
Descriptive Statistics
Frequencies and percentages were calculated for pre-intervention risk education and
post-intervention risk education. The most frequently observed category of pre-intervention risk
education was Y (n = 15, 25%). This statistic reflects that only 25% of patients were provided
risk education pre-intervention. The most frequently observed category of post-intervention risk
education was Y (n = 24, 100%), revealing that all patients were provided risk education during
the intervention period.
Frequencies and percentages were calculated for pre-intervention follow up and postintervention follow up. The most frequently observed category of pre-intervention follow-up was
N (n = 19, 95%), demonstrating that only 5% of patients (1 of 20) had a follow-up plan
documented in the EMR. The most frequently observed category of post-intervention follow-up
was Y (n = 18, 75%), reflecting that three-fourths of CBU patients had a follow-up plan
documented in their EMR after the practice change was initiated.
Chi-square Test of Independence
A Chi-square Test of Independence was conducted to examine whether the differences
in pre-intervention follow-up (5%) and post intervention follow-up (75%) were statistically
significant. Results of the Chi-square test was as follows, χ2(1) = 8.24, p = .004; there was a
statistically significant increase in documentation of a follow-up plan from the pre-intervention to
post-intervention period. Initial statistical analyses to evaluate the differences in percentage of
risk education could not be undertaken using Chi-square analyses because post-intervention
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data were not dichotomous: the only category was Y (yes), with risk education being provided
for all 24 patients. To provide an estimate of statistical significance in the differences in
documentation of risk education pre-intervention (25%) to post-intervention (100%), analyses
were conducted using a statistical violation. Three of the Ys were changed to N so that the postintervention percentage was 87.5%, rather than 100%. Conducting the chi-square analysis with
this statistical violation revealed that the percentage point increase in risk education rates was
statistically significant χ2(1) = 10.59, p = .001.
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CHAPTER 5
DISCUSSION
This EBP project was designed to answer the PICOT question: Among pain
management providers in an outpatient clinic, does the use of a standardized quarterly triad tool
with concurrent benzodiazepine use (CBU) assessment promote provider adherence to the
monitoring and decrease of CBU, compared to the current practice of not using the QTT, within
a 90-day period? The project was implemented at a specialty pain management clinic located in
the Midwest. It was expected that the implementation of a QTT consisting of UDSs, PDMP, and
medication reconciliation in quarterly patient visits in EMR would promote provider adherence to
the QTT, resulting in an increase in both patient education and follow up planning. The
multifaceted implementation was comprised of (a) provider education, (b) inclusion of the QTT
in the EMR through the use of a quick auto-text application, (c) use of an MA clinical champion,
and (d) a team-based approach. This chapter will include an explanation of project findings,
evaluation of key factors that contributed to the success of this project, project limitations and
implications for future projects of this nature and conclusive findings. The theoretical framework
and model used to guide this EBP will be evaluated.
Explanation of Findings
The findings of this project reflected those of the supportive literature indicating that tools
like UDSs and PDMPs should be utilized routinely in addition to medication review and patient
reports to screen for CBU. Implementation of the multifaceted strategy required the buy in of key
stakeholders. It readily became apparent that implementation would benefit from the use of a
clinical champion to facilitate prescriber’s adoption of the behavior change. A medical assistant
was chosen for this position, and her assistance was invaluable in printing out the quarterly visit
summaries, PDMP and UDSs without negatively impacting the workflow for the day. Providers
had been seeing typically 80 to 100 patients per day prior to implementation and that
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productivity was not reduced during the implementation phase. Providers workday time was not
expanded as a result of participation in the practice change and they were still able to see the
same number of patients in the same number of scheduled hours, without staying late or
skipping lunch.
The strategy of minimally impacting workflow likely added to the adoption rate of
providers. Yet, one of the six prescribing providers was a non-adopter of the practice change.
The three main factors reported for not adopting the change in practice were (a) the task of an
additional step in otherwise routine documentation, (b) the belief that behavioral change would
be temporary and would be dismissed after project completion, and (c) compared to other
providers, the DNP student spent the shortest amount time educating and reminding this
provider about the utility of the tool due to time constraints. Although this provider was
accustomed to the previous practice of patient risk evaluation, it cannot be determined if
additional education time and reinforcement of practice change would have ultimately changed
behavior or if an alternative means of education and reinforcement would have enhanced
adoption of practice change. One could question if the physician would have documented the
use of the QTT if the change in practice were initiated by a physician colleague or if it were
mandatory or incentivized.
Adopting providers noted that the implementation strategies did not negatively impact
their practice and that the use of the QTT in the EMR made the change in documentation
seamless. This impression was reflected in the increased documentation of risk education from
25% of patients pre-intervention to 100% post-intervention. And, although to a lesser extent, the
use of the EMR led to an increase in adoption rates of documentation of a patient-specific
follow-up plan from 15% to 75% a statistically significant increase (X2 = 8.235, p =.004). This
additional step required an individualized approach which took additional time and planning by
the prescribing providers; thus, it was not surprising that the adoption rates did not reach 100%.
Still, the adopting providers reported the benefit of being able to quickly document practices that
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addressed patient safety. An enhanced patient safety is further inferred by the supportive
evidence of increased risk education and follow up planning documentation from the providers
who adopted and used the tool.
The DNP student was a prescribing provider for this project, and it was important to
evaluate the data with and without her documentation included. It was important to note that
even the DNP student, project leader, had 100% of follow up plans documented within the
twelve weeks of the project implementation likely because her awareness of the project was
heightened. The two providers who did not have 100% follow up education noted that some
patient specific follow up plans entailed coordination and discussions with providers outside the
clinic and documentation could not be completed until this was done. Another reason was that
some patients were discharged a result of recurrent non-prescribed CBU, a violation of their
opioid contract.
Evaluation of Applicability of Theoretical and EBP Frameworks
This project was guided systematically by Kotter’s model of change theoretical
framework and the PARIHS EBP model. The application is discussed below.
Theoretical Framework
The first step of Kotter’s model of change is the creation of the sense of urgency. While
the DNP student facilitator was able communicate the necessity of adapting the tool
immediately by discussing national data as outlined in chapter 1 and internal data from the
clinic, one of six providers did not adopt the tool at the point of initiation. Thee of the five
remaining providers adopted the tool reluctantly with the expectation that if the project did not
confer any efficacy to CBU risk education and follow up, they would abort the behavioral change
after the implementation period and finally, two of the five adopted because they were eager to
better practice outcomes. The notion that there was a sense of urgency did not appear to be a
huge driver on attitudes that led to behavioral changes.
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The second step of Kotter’s model of change was evident in the selection of the medical
assistant (MA) champion. However, the appointment of the MA champion also created the
challenge of the engagement and inclusion of the rest of the supportive staff who felt like they
were not as important to the project. Initially, there was also marked concern from the other MAs
who felt that their daily routine would be adjusted to accommodate the project. The MA
champion was instrumental in getting the other supportive staff to rally around the project.
The third step was the creation of a vision and a realistic implementation strategy for
bringing the vision to fruition. The DNP student facilitator had 90 days to implement the project
which guided the timeline. To allow for ease of documentation, the QTT was included in the
EMR through an auto-text application. However even with the ease in documentation, not all
providers adopted the QTT.
Step four of the Kotter model was communicating the vision of going beyond “just
abiding with the guidelines”. Personal stories of improved patient outcomes were shared by the
DNP student. There was very little to evaluate on the impact of this step as this was tied in to
step 3.
Step five which included staff empowerment for behavioral change and elimination of
barriers that inhibit successful change was apparent in that this project did not require any
additional staffing hours or changes in the clinical budget. The use of the auto-text inclusion also
streamlined the documentation process. However, there was some generalized anxiety among
staff over additional steps in documentation and data collection to aide in the review of the 2
additional components of UDSs and PDMP print outs in addition to medication reconciliation to
evaluate for compliance. There was a variation in practice in that some providers required for
the assisting MA to review and report identified CBU before they went into the rooms and saw
that patients, while some providers completed their reviews independently from pre-printed
UDSs and PDMPs.
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Step six of Kotter’s theory was outlined by the routine celebration of biweekly successes.
However, smaller sample groups made it difficult to report impactful change. One of the
incidental successes was the increased trend in CBU risk education on patients who were not
on CBU. There was an overall increase in provider-patient risk education.
Step seven was outlined in the DNP student’s persistence in ensuring that providers
complied with the use of the QTT through constant reminders. However due to work flow
variations, the DNP student was unable to constantly reach out to the non-adapting provider to
impart behavioral change through adherence.
Step eight which entailed the nourishment of the new culture to make it last became
apparent as providers not only adapted the tool, but supportive staff continued to print out
PDMPs and UDSs prior to clinic visits. As a result, patients who were seen on their quarterly
visits who did not have a UDS within the last three months had UDS orders to evaluate
compliance. Sustainability of the project will need more time given that the outcomes indicated
are all within the 90 days of the project implementation phase.
Overall, while the Kotter theory provided a benchmark that guided the implementation
process, positions did not always change with the stepwise transitions. Another finding that was
that some of the steps overlapped each other.
EBP Framework
The PARIHS (Promoting Action on Research Implementation in Health Services)
framework was used in the design and implementation of this EBP project. The main strength of
the EBP model was the fact that the DNP student facilitator was also part of the staff at this
clinic with established credibility and authority within the organization. The DNP student
gathered research evidence from studies and clinical practice guidelines to support project
implementation. Secondly, the DNP student also had clinical experience as a pain specialist
working within the clinical context. As a pain provider, the DNP facilitator understood the EMR
which allowed for easy navigation, creation and inclusion of the QTT within the documentation
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system. The main limitation of the framework was the inability to assess how each of the
elements of the framework impacted the implementation of the project, as it appeared that
facilitation of the project took precedence over evidence and context given the timelines and
the reason for the project which was to change clinical outcomes but also to meet the
educational needs of the DNP facilitator .
Strengths and Limitations of the EBP Project
Strengths
The main strength of the EBP project was the collaboration from leadership providers
and support staff who embraced the project and its facilitation. Another strength of the EBP
project was that it did not require any additional funding, staffing or budget changes to support
its implementation. The DNP student facilitator had strong support from faculty advisors who
despite the pressures affiliated with project implementation and evidence review, guided the
DNP facilitator relentlessly through their own personal experiences from past projects. Finally,
another strength was the current climate of the opioid crisis which automatically created the
sense of urgency and a need to better practice outcomes in an effort to promote patient safety.
Limitations
The main limitation was in the evidence search. Due to ethical considerations which
eliminated randomization of screening, the only levels of evidence available were levels IV and
V which entailed practice guidelines and expert opinions. Another limitation was a very small
sample group which challenges the generalization of findings. As in the evaluation of patients on
CBU, the initial data yielded 38.46%, while the post intervention data yielded a 15.58% CBU,
which indicates that other trends other than the QTT might have already been impacting
behavioral changes, which makes it difficult to isolate this the outcome of decreased CBU rates
to the implementation of the project. This could have also been impacted by the fact that data
was only collected on Wednesdays.
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Implications for the Future
Practice
As clinicians continue to implement practice changes to address patient safety in the
opioid epidemic climate, this project demonstrates that the role of the Doctor of Nursing Practice
is instrumental in the evaluation and incorporation of evidence-based research to better patient
outcomes. The DNP student facilitator was able to chaperone the implementation of evidence
practice change which in turn imparted behavioral change across a multidisciplinary team of
healthcare providers.
Theory
The Kotter theoretical framework and PARIHS model provided a systematic path for the
DNP facilitator to navigate the obstacles that arise from transitions. These two theoretical
frameworks provided a systematic approach which allowed for the incorporation of evidence into
practice while mitigating resistance associated with the process of change.
Research
Future research studies that entail larger sample groups (both provider and patients) and
longer implementation time frames should be considered before findings can be generalized.
While the project measured risk education and follow up planning as indicators for CBU
reduction, further research studies should be done to measure actual CBU reduction as
evidenced by patient census.
Education
The project opened communication lines for well needed provider and patient education
on effective strategies to mitigate CBU. Follow up planning also incidentally created the need for
patients who continue to utilize both BZD and opioids due to medical necessity to complete
consent forms indicating that while they were aware of the existing risks, they opted to continue
with dual therapies for medical reasons. Other incidental follow-up finding was the inclusion of
rescue Naloxone in patients who were identified to aide in risk mitigation.
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Conclusion
Conclusively, safe chronic opioid prescribing with regards to mitigating and avoiding
concurrent benzodiazepine and opioid use is necessary in combating the opioid epidemic. This
EBP project answered the question as posed by the PICOT: Among pain management
providers in an outpatient clinic, does the use of a standardized quarterly triad tool with
concurrent benzodiazepine use (CBU) assessment, promote provider adherence to the
monitoring and decrease of CBU, compared to the current practice of not using the QTT within a
90-day period? The post intervention outcome was yes. This project also demonstrated that the
role of the DNP is crucial in the opioid crisis climate to aide in the research evaluation and
implementation to promote safe opioid prescribing patterns
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APPENDIX A

JHNEBP MODEL AND
TOOLS- PERMISSION

Thank you for your submission. We are happy to give you permission to use the
JHNEBP model and tools in adherence of our legal terms noted below:

•

You may not modify the model or the tools without written approval from Johns
Hopkins.

•

All reference to source forms should include “©The Johns Hopkins Hospital/The Johns
Hopkins University.”

•

The tools may not be used for commercial purposes without special permission.
If interested in commercial use or discussing changes to the tool, please
email ijhn@jhmi.edu.
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APPENDIX B
Provider Level

CBU

Patient

Follow Up

Yes

Education

Education

Yes/ No

Yes/ No

Notes
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APPENDIX D
Quarterly Triad Tool (QTT)
Quarterly visit
UDS within 3 months: Y_ N_
PDMP Consistent: Y_N_
CBU Identified: Y_N_
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APPENDIX E
Provider
Level

QTT used
•

QV

•

UDS

•

PDMP

CBU

Patient

Follow Up

Yes

Education

Education

Yes/ No

Yes/ No

Notes
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